Investors Purchase Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) was the target of unusually large options trading on Friday. Stock investors purchased 32,948 call options on the company. This is an increase of approximately 1,371% compared to the typical daily volume of 2,240 call options.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 1,942,629 shares of company stock valued at $23,071,486. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently added to or reduced their stakes in the company. Penn Davis Mcfarland Inc. lifted its stake in Roivant Sciences by 1.0% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 1,649,026 shares of the company’s stock worth $19,508,000 after purchasing an additional 16,832 shares during the last quarter. Miracle Mile Advisors LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth about $148,000. Wedmont Private Capital purchased a new position in shares of Roivant Sciences in the fourth quarter worth about $134,000. ORG Wealth Partners LLC increased its holdings in shares of Roivant Sciences by 85.7% in the fourth quarter. ORG Wealth Partners LLC now owns 18,240 shares of the company’s stock worth $216,000 after buying an additional 8,417 shares during the period. Finally, Nordea Investment Management AB increased its holdings in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after buying an additional 52,031 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 2.4 %

Shares of ROIV stock opened at $11.15 on Friday. The business has a 50-day moving average price of $11.79 and a two-hundred day moving average price of $11.59. Roivant Sciences has a 12-month low of $9.69 and a 12-month high of $13.06. The firm has a market cap of $8.12 billion, a P/E ratio of 1.97 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.